Anti-CD79b-MCC-DM1 can completely regress subcutaneous and disseminated xenograft tumors. Anti-CD79b-MCC-DM1 causes tumor regression in a disseminated tumor model of NHL. Mice were injected intravenously via tail vein with 5 × 10⁶ BJAB-luc cells and grouped into 2 even groups based on tumor burden as evaluated by BLI 9 days after cell injection and treated 2 times 1 week apart with 5 mg ADC/kg mouse (99 μg conjugated DM1/kg mouse) anti-CD79b(SN8)-MCC-DM1 or 5 mg ADC/kg mouse (108 μg conjugated DM1/kg mouse) trastuzumab-MCC-DM1. Tumor burden was evaluated by weekly BLI and mice were euthanized if they became moribund. (A) Kaplan-Meier survival plot of the treated mice. (B) Representative bioluminescence images showing disease progression in a trastuzumab-MCC-DM1 and an anti-CD79b-MCC-DM1 treated mouse. (C) Quantitation of mean bioluminescence intensity for individual animals over time for treatment and control groups. The plot shows variation in signal normalized to the signal intensity just before the start of treatment (day 9). (D) Anti-CD79b-MCC-DM1 can be curative in xenograft models. Growth curves for subcutaneously implanted BJAB cells. Cells were allowed to grow to an average of 200 mm³ and then given 3 weekly doses intravenous of 79 μg antibody linked drug/kg (≈5 mg/kg) anti-CD79b(SN8)-MCC-DM1 or trastuzumab-MCC-DM1, or 10 mg/kg trastuzumab.